Physician profile
Robert J Boulware
NPI 1801978259
$7,330.37
in general payments reported to CMS, 2019-2025
63 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $764 · 2021: $1,249 · 2022: $988 · 2023: $1,241 · 2024: $1,028 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.12 | 2021-2025 | Ubrelvy, Linzess, Qulipta |
| Lilly USA, LLC | $467.91 | 2019-2025 | Mounjaro, Zepbound, Olumiant |
| Novo Nordisk INC | $422.22 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $391.32 | 2019-2025 | |
| Amgen INC. | $322.56 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $241.94 | 2020-2025 | Airsupra, Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $237.31 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $221.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.46 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $219.37 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $218.30 | 2023-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $214.47 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.33 | 2019-2021 | |
| Abbott Laboratories | $183.73 | 2022-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $167.95 | 2019-2024 | Yupelri |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boulware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.